Outcome of small node-negative ER+/HER2+and ER-/HER2+breast cancers might be different

被引：0
|
作者：
Altundag, Kadri [1 ]
机构：
[1] MKA Breast Canc Clin, Ankara, Turkey
来源：
JOURNAL OF BUON | 2020年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：583 / 583
页数：1
相关论文
共 50 条
  • [41] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    CANCER RESEARCH, 2020, 80 (04)
  • [42] Palbociclib Ups PFS in HER2-/ER+ Breast Cancer
    不详
    CANCER DISCOVERY, 2014, 4 (06) : 624 - 625
  • [43] Targeted therapies for ER+/HER2- metastatic breast cancer
    Mutsuko Yamamoto-Ibusuki
    Monica Arnedos
    Fabrice André
    BMC Medicine, 13
  • [44] Complex rearrangements fuel ER+ and HER2+ breast tumours
    Houlahan, Kathleen E.
    Mangiante, Lise
    Sotomayor-Vivas, Cristina
    Adimoelja, Alvina
    Park, Seongyeol
    Khan, Aziz
    Pribus, Sophia J.
    Ma, Zhicheng
    Caswell-Jin, Jennifer L.
    Curtis, Christina
    NATURE, 2025, : 510 - 518
  • [45] T1b with ER negative, HER2-positive, and node-negative breast cancer patients might get benefit from adjuvant chemotherapy
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (05): : 2529 - 2530
  • [46] ANALYSIS OF DIFFERENT SYMPTOMS IN ESTROGEN RECEPT OR POSITIVE (ER+) OR NEGATIVE (ER-) BREAST CARCINOMAS (BC)
    COCCONI, G
    CECI, G
    BOZZETTI, C
    CANALI, F
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 340 - 340
  • [47] Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+breast cancer patients
    Risi, E.
    Grilli, A.
    Migliaccio, I.
    Biagioni, C.
    Guarducci, C.
    Bonechi, M.
    McCartney, A.
    Vitale, S.
    Biganzoli, L.
    Bicciato, S.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] HER2−/ER+-Brustkrebs: fehlende Taxoleffektivität?HER2−/ER+ breast cancer: lack of effectiveness of taxol?
    N. Bangemann
    Der Onkologe, 2008, 14 (2): : 198 - 200
  • [49] Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER+/HER2-breast cancer
    Poorvu, P. D.
    Gelber, S. I.
    Rosenberg, S. M.
    Ruddy, K. J.
    Tamimi, R. M.
    Collins, L. C.
    Peppercorn, J.
    Schapira, L.
    Borges, V. F.
    Come, S. E.
    Warner, E.
    Jakubowski, D. M.
    Russell, C.
    Winer, E. P.
    Partridge, A. H.
    CANCER RESEARCH, 2019, 79 (04)
  • [50] Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
    Filipits, Martin
    Dubsky, Peter
    Rudas, Margaretha
    Greil, Richard
    Balic, Marija
    Bago-Horvath, Zsuzsanna
    Singer, Christian F.
    Hlauschek, Dominik
    Brown, Krystal
    Bernhisel, Ryan
    Kronenwett, Ralf
    Lancaster, Johnathan M.
    Fitzal, Florian
    Gnant, Michael
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3865 - 3872
12345